PMID: 18203081Jan 19, 2008Paper

Minimally invasive pterygium surgery: a new approach for prevention of recurrence

European Journal of Ophthalmology
N BozkirA Maden

Abstract

To introduce a novel approach for pterygium excision, to report recurrence rates, and to compare with conjunctival autografting. A comparative, prospective clinical case series design was used. The study population consisted of 155 patients with unilateral primary or recurrent pterygia. All patients underwent pterygium excision, either by conventional conjunctival autografting (Group A) or by the minimally invasive pterygium excision (MIPE) technique (Group B). The new technique involves making a limbal incision of the conjunctiva through the body of pterygium, removing the head of the pterygium by blunt dissection, keeping the adjacent Tenon capsule intact, and performing a small conjunctival autograft to cover the epithelial defect. The recurrence rate of each technique was compared statistically. There were 84 patients in Group A and 71 patients in Group B. The recurrence rates were 18% at 1 year after surgery in the conjunctival autografting technique and 4.2% in the MIPE technique. The MIPE technique had significantly lower recurrence rates compared with conjunctival autografting technique (p<0.0001). The MIPE technique had lower recurrence rate and fewer postoperative complications than the conjunctival autografting techn...Continue Reading

References

Nov 1, 1992·Ophthalmology·R S RubinfeldM G Speaker
May 1, 1989·Ophthalmology·K R Kenyon, S C Tseng
Jul 1, 1988·Survey of Ophthalmology·P A Jaros, V P DeLuise
Nov 1, 1985·Ophthalmology·K R KenyonM E Hettinger
Jan 1, 1994·Ophthalmology·J A McCoombesG P Isbell
Feb 3, 2000·International Journal of Radiation Oncology, Biology, Physics·Y NishimuraO Ishida
Oct 19, 2004·The British Journal of Ophthalmology·F RaiskupJ Frucht-Pery

❮ Previous
Next ❯

Citations

Mar 16, 2018·Vestnik oftalmologii·A V Petrayevsky, K S Trishkin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.